Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic poorly differentiated neuroendocrine carcinoma~* Unknown primary site~* Able to perform activities of daily living with minimal assistance~* Measurable or evaluable disease~* Adequate bone marrow, liver functions and kidney function~* No previous treatment with chemotherapy~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Previous malignancy within five years~* Women pregnant or lactating~* Recent history of cardiovascular disease~* Meningeal metastases~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).